Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 01, 2024 12:50pm

114 Views

Post# 35857421

RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

February 01, 2024 - Merck is interested in deals between $1-15 billion, with the $10 billion-plus range being the sweet spot.

Merck is narrowing the use of an antibody-drug conjugate (ADC) acquired from VelosBio to focus solely on hematological malignancies.

Merck acquired Phase 1/2 ADC company VelosBio in 2020 for US$2.75 Billion.

https://www.fiercebiotech.com/biotech/merck-plans-more-phase-3-launches-2023-while-voracious-bd-appetite-remains

https://www.merck.com/news/merck-to-acquire-velosbio/

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing